• Danielius Serapinas, Brigita Sitkauskiene, and Raimundas Sakalauskas.
• Department of Pulmonology and Immunology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania ; Mykolas Romeris University, Vilnius, Lithuania.
• Arch Med Sci. 2012 Dec 20; 8 (6): 105310581053-8.

IntroductionChronic obstructive pulmonary disease (COPD) has been recently defined as a systemic pulmonary inflammatory disease, and congenital α1 antitrypsin deficiency is one of the well-established genetic risk factors for chronic obstructive pulmonary disease. The aim of our study was to evaluate the possible associations of α1 antitrypsin with inflammatory markers - CRP, sCD14, TNF-α, sTNFR-1, and sTNFR-2 - in patients with COPD with different α1 antitrypsin genotypes.Material And MethodsSerum biomarkers from patients (n = 355) with COPD, defined according to the GOLD criteria, were analyzed using commercial ELISA kits; α1 antitrypsin concentrations were determined by nephelometry, and α1 antitrypsin phenotyping was carried out by means of isoelectric focusing.ResultsNo significant differences in CRP, TNF-α, sTNFR-1, sTNFR-2, and sCD14 levels were found comparing COPD patients with different genotypes. In patients without α1 antitrypsin deficiency (PI*MM), a significant negative correlation between lung function (FEV(1)) and serum α1 antitrypsin (r = -0.522, p = 0.03) and CRP concentration (r = -0.590, p = 0.011) was detected. The level of α1 antitrypsin positively correlated with: a) CRP concentration (r = 0.671, p = 0.005), b) sCD14 (r = 0.510, p = 0.008) and c) sTNFR-1 (r = 0.567, p = 0.007).ConclusionsIn patients without α1 antitrypsin deficiency, the positive association of α1 antitrypsin concentration with CRP, sCD14, and sTNFR-1 and the negative association with FEV(1) show the importance of α1 antitrypsin as a marker of systemic inflammation.

3 keywords...

hide…